



Sinclair Pharma plc Notice of Interim Results

13th February 2009, Godalming, UK. Sinclair Pharma plc (SPH.L), the international specialty pharma company, today announced it will release its Interim Financial Results for the period to 31 December 2008 on Thursday, 26th February, 2009.

In conjunction with the financial results release there is an analyst presentation scheduled at 9:30am on Thursday 26th February (UK time). Interested parties will be able to listen live via conference call with a replay available for 10 days.

The presentation will be hosted by the Company's Chief Executive Officer, Dr Michael Flynn, and Chief Financial Officer, Jerry Randall.

Announcement: Sinclair Pharma plc Interim Financial Results

Date: Thursday, 26th February, 2009

Time: 9:30am (UK time)

Location: Teathers' Offices, London (by invitation only)

Conference call details are available on request; please contact Joey Whineray at Capital MS&L Joanna.whineray@capitalmsl.com.

- End -

For further information please contact:

Sinclair Pharma plc

Dr Michael Flynn, CEO

Jerry Randall, CFO

Mariam Rawat, Communications & Investor relations

Tel: +44 (0)1483 410 600

MRawat@sinclairpharma.com

Capital MS&L

Mary Clark / Anna Mitchell

Tel +44 (0)20 7307 5340

Notes to editors:

About Sinclair Pharma plc www.sinclairpharma.com

Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 80 countries.

Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short timeframe. Sinclair focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward- looking statements due to a variety of factors.